Abstract | BACKGROUND: Tumor hypoxia may be associated with treatment resistance, cell proliferation, and metastatic potential, which contribute to poor prognosis. Complementary techniques for detecting hypoxia, cell growth, and metastases are required to study these relationships. OBJECTIVES: The purpose of this study was to demonstrate the clinical feasibility of quantitative hypoxia detection with pimonidazole, a novel hypoxia marker, and to correlate hypoxia with S-phase markers of tumor proliferation. METHODS: RESULTS: No clinical toxic effects were associated with pimonidazole administration. Immunostaining with pimonidazole antibody was observed in 9 of 10 tumors, suggesting that hypoxia is a common occurrence in cervical carcinoma. Quantitatively, tumors that had large numbers of hypoxic cells had the greatest percentage of S-phase cells, but some tumors with smaller amounts of hypoxia also had substantial numbers of S-phase cells. CONCLUSION:
Pimonidazole can be used for qualitative and quantitative assessment of tumor hypoxia.
|
Authors | M A Varia, D P Calkins-Adams, L H Rinker, A S Kennedy, D B Novotny, W C Fowler Jr, J A Raleigh |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 71
Issue 2
Pg. 270-7
(Nov 1998)
ISSN: 0090-8258 [Print] United States |
PMID | 9826471
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 1998 Academic Press. |
Chemical References |
- Biomarkers
- Nitroimidazoles
- Proliferating Cell Nuclear Antigen
- pimonidazole
|
Topics |
- Biomarkers
- Cell Division
- Cell Hypoxia
- Female
- Humans
- Immunohistochemistry
- Nitroimidazoles
(pharmacology)
- Proliferating Cell Nuclear Antigen
(analysis)
- S Phase
- Uterine Cervical Neoplasms
(metabolism, pathology)
|